NBTX VS TOI Stock Comparison

Performance

NBTX
51/100

NBTX returned -7.36% in the last 12 months. Based on the other stocks in its sector with an average return of -7.41%, its performance is above average giving it a grade of 50 of 100.

TOI
100/100

TOI returned 7.25% in the last 12 months. Based on SPY's performance of -12.94%, its performance is above average giving it a score of 100 of 100.

Sentiment

NBTX
63/100

NBTX had a bullish sentiment score of 63.40% across Twitter and StockTwits over the last 12 months. It had an average of 30.90 posts, 5.83 comments, and 30.90 likes per day.

TOI

"Sentiment" not found for TOI

Volatility

NBTX
20/100

NBTX has had a lower than average amount of volatility over the last 12 months giving it a grade of 20 of 100.

TOI
51/100

TOI has had a higher than average amount of volatility over the last 12 months giving it a score of 51 of 100.

Technicals

NBTX

"Technicals" not found for NBTX

TOI
79/100

TOI receives a 78 of 100 based on 14 indicators. 10 are bullish, 2 are bearish.

Earnings

NBTX

"Earnings" not found for NBTX

TOI
16/100

TOI has missed earnings 3 times in the last 20 quarters.

Profit

NBTX

"Profit" not found for NBTX

TOI
20/100

Out of the last 16 quarters, TOI has had 3 profitable quarters and has increased their profits year over year on 2 of them.

All score calculations are broken down here to help you make more informed investing decisions

Nanobiotix S.A. American Depositary Shares Summary

Nasdaq / NBTX

Healthcare

Biotechnology

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

The Oncology Institute, Inc. Common Stock Summary

Nasdaq / TOI

Healthcare

Medical - Care Facilities

The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.

Power up your portfolio